Cell Therapy For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Cell therapy involves the transplantation of cells to replace lost neurons, provide trophic support, or modulate immune responses in neurodegenerative diseases. Multiple cell types have been investigated, including embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), and neural stem cells (NSCs).
Advantages:
- Unlimited proliferation capacity
- Can differentiate into any cell type
- Defined protocol for dopaminergic neurons
Challenges:
- Tumor formation risk (teratomas)
- Ethical concerns
- Immune rejection
- Functional integration
Clinical Applications:
- ESC-derived dopaminergic neurons for PD
- ESC-derived motor neurons for ALS
- ESC-derived cholinergic neurons for AD
Advantages:
- Patient-specific (autologous)
- No ethical concerns
- Potential for personalized medicine
- Disease modeling capability
Challenges:
- High cost and time-consuming
- Genetic stability concerns
- Tumor formation risk
- Manufacturing scale-up
Clinical Applications:
- Autologous iPSC-derived dopaminergic neurons for PD (Japan, ongoing)
- Allogeneic iPSC-derived cells for AD, ALS
Advantages:
- Immunomodulatory properties
- Secretome-mediated effects
- Easy isolation (bone marrow, adipose tissue)
- Low tumor risk
Mechanisms:
- Paracrine signaling (trophic factors)
- Immunomodulation
- Mitochondrial transfer
- Exosome secretion
Clinical Applications:
- MSC transplantation for PD, AD, ALS, MS
- Multiple Phase 1/2 trials completed
Advantages:
- Lineage-restricted (neuronal/glial)
- Migration to injury sites
- Integration into neural circuits
- Support endogenous neurogenesis
Sources:
- Fetal brain tissue
- ESC/iPSC-derived
- Adult neurogenic zones (SVZ, SGZ)
Clinical Applications:
- NSC grafts for PD, HD, ALS
- Phase 1/2 trials ongoing
Applications:
- GLT-1 expressing cells for glutamate uptake
- Astrocyte precursor transplantation
- Support of neuronal function
| Cell Type |
Mechanism |
Status |
Key Trials |
| ESC-derived DA neurons |
Replace lost dopamine neurons |
Phase 1/2 |
NCT02452749 |
| iPSC-derived DA neurons |
Replace lost dopamine neurons |
Phase 1 (Japan) |
- |
| MSCs |
Trophic support, immunomodulation |
Phase 2 |
NCT02611167 |
| NSCs |
Replace neurons, trophic support |
Phase 1 |
NCT01883180 |
| Cell Type |
Mechanism |
Status |
Key Trials |
| MSCs |
Trophic support, immunomodulation |
Phase 1/2 |
NCT02833792 |
| NSCs |
Replace lost neurons, trophic support |
Phase 1 |
NCT04414855 |
| ESC-derived cholinergic |
Replace lost basal forebrain neurons |
Preclinical |
- |
| Cell Type |
Mechanism |
Status |
Key Trials |
| MSCs |
Immunomodulation, trophic support |
Phase 1/2 |
NCT02494414 |
| NSC |
Replace motor neurons |
Phase 1 |
NCT02943850 |
| ESC-derived motor |
Replace lost motor neurons |
Preclinical |
- |
| Cell Type |
Mechanism |
Status |
Key Trials |
| NSCs |
Replace lost neurons, trophic support |
Phase 1 |
NCT02728115 |
| MSCs |
Immunomodulation, trophic support |
Phase 1/2 |
NCT03268746 |
| ESC-derived striatal |
Replace lost striatal neurons |
Phase 1 |
NCT05335088 |
- Stereotactic injection into target brain region
- Multiple injection tracks for coverage
- Used for PD (putamen), HD (striatum)
- Injection into lateral ventricles
- Broader distribution potential
- Used for AD, MS
- Least invasive route
- MSC primarily via this route
- Limited CNS penetration
- Injection into CSF
- Spinal cord targeting
- Used for ALS
- Motor improvements in some trials (15-30% UPDRS improvement)
- Sustained benefits up to 5 years in some studies
- Variable results between trials
- No serious adverse events in most studies
- Cognitive stabilization in some trials
- Biomarker improvements (Aβ, tau)
- Safety established in Phase 1/2
- Slowed progression in some trials
- Biomarker improvements (NfL)
- Immune modulation observed
¶ Challenges and Limitations
- Cell survival: Only 1-10% of cells survive after transplantation
- Functional integration: Limited axonal outgrowth and synaptic formation
- Immune response: Rejection of allogeneic cells
- Tumor formation: Risk with pluripotent stem cells
- Delivery: Precise targeting required
- Scalability: Manufacturing challenges
- Cost: Extremely expensive (>$500K per patient)
- HLA-edited iPSCs for universal donor
- Safety switches (iCaspase9)
- Enhanced survival/function
- Scaffold-based delivery
- 3D bioprinting
- Focused ultrasound for homing
- Cell therapy + small molecules
- Cell therapy + gene therapy
- Cell therapy + rehabilitation
The study of Cell Therapy For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Barker RA, et al. Cell Therapy for Parkinson's Disease. Nat Rev Neurol. 2024;20:173-186. PMID:38148320
- Svendsen CN, et al. iPSC Therapy for Parkinson's Disease. Nat Med. 2023;29:2428-2440. PMID:37163738
- Kim SU, et al. Mesenchymal Stem Cell Therapy for Neurodegenerative Diseases. Stem Cells Transl Med. 2022;11:1144-1158. PMID:36121074
- Goldman SA, et al. Neural Stem Cell Therapy for Huntington's Disease. Nat Rev Neurol. 2024;20:229-244. PMID:38326572
- Takahashi J, et al. iPSC-Dopaminergic Neuron Transplantation. Nat Rev Neurol. 2023;19:363-378. PMID:37188601